Filing Flows › Kura Oncology (KURA) › Q2 2026
Kura Oncology (KURA) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 12, 2026
Kura Oncology (KURA) reported revenue of $20.9M for the second quarter 2026 (Q2 2026), +37% from a year earlier and +14% from the quarter before. Operating margin was -349.8%, net loss $68.3M (327.3% of revenue).
Kura Oncology, Q2 2026: revenue $20.9M (+36% year over year), operating margin -349.8%, net loss $68.3M, operating cash flow −$62.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.9M | +14% | +37% |
| Operating profit | −$73.0M | — | — |
| Net earnings | −$68.3M | — | — |
| Operating cash flow | −$62.5M | — | — |
What changed
Revenue was $20.9M in Q2 2026, up 37% year over year and up 14% from the previous quarter. License and Collaboration Revenue was the largest line at 56% of revenue. License and Collaboration Revenue declined 23%.
Operating costs exceeded revenue by $73.0M, an operating margin of -349.8%. Total costs grew 7% against revenue growth of 37%. The fastest-growing cost line was SG&A (+26%). The quarter ended with a net loss of $68.3M, narrower than the previous quarter's $73.3M loss.
Operating cash flow was −$62.5M. Non-cash charges added back $369K of depreciation and $8.2M of share-based compensation. Capital expenditures of $656K exceeded it, leaving free cash flow of −$63.2M.
Questions
What was Kura Oncology's revenue in the second quarter 2026?
Kura Oncology (KURA) reported revenue of $20.9M for the second quarter 2026 (Q2 2026), +37% from a year earlier and +14% from the quarter before.
Was Kura Oncology profitable in the second quarter 2026?
Operating loss was $73.0M (-349.8% of revenue) and net loss $68.3M.
Source: Kura Oncology 10-Q on SEC EDGAR.